39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

Actinic Keratosis: Pathogenesis & Sandpaper Morphology

Actinic keratosis (AK, solar keratosis) is the most common premalignant cutaneous neoplasm encountered in outpatient medicine, affecting more than 40 million Americans. It represents an early, intraepidermal stage in the biological continuum toward invasive cutaneous squamous cell carcinoma.

Molecular Pathogenesis & UV Carcinogenesis

• UVB Radiation (290-320 nm): The primary etiological driver. UVB induces specific signature mutations characterized by cytosine-to-thymine (C-to-T) and CC-to-TT dipyrimidine transitions within the TP53 tumor suppressor gene of basal epidermal keratinocytes.
• Clonal Proliferation: Loss of p53-mediated DNA repair and apoptosis permits dysplastic atypical keratinocytes to proliferate. These atypical cells display nuclear pleomorphism, hyperchromasia, disordered architectural maturation, and loss of polarity, remaining strictly confined above the basement membrane (intraepidermal).

Clinical Presentation: The "Sandpaper" Lesion

• Morphology: An ill-defined, erythematous to yellowish-brown macule or thin papule topped by a rough, dry, adherent scale.
• Board Exam Classic Clue: "Feels like coarse sandpaper"! Actinic keratoses are often tactilely detected on light palpation before they are visually obvious.
• Distribution: Chronic sun-exposed anatomical sites in fair-skinned individuals (Fitzpatrick skin types I-II): bald scalp, forehead, cheeks, vermilion border of the lower lip (actinic cheilitis), ears, dorsal hands, and extensor forearms.
• Hypertrophic AK & Cutaneous Horn: Thick, hyperkeratotic lesions may form an elevated, conical projection of compacted keratin known as a cutaneous horn. A biopsy of the base is mandatory because up to 15% to 20% harbor invasive squamous cell carcinoma at their foundation.

Malignant Transformation Risk

• Transformation Rate: The individual annual rate of malignant transformation from a single AK to invasive cutaneous squamous cell carcinoma is estimated at 0.1% to 1% per lesion per year.
• Field Cancerization & Cumulative Risk: Because patients typically present with dozens of subclinical and clinical AKs across an entire sun-damaged anatomical field, the lifetime probability of developing an invasive SCC in a patient with multiple AKs reaches 10%. Furthermore, approximately 60% to 65% of all primary cutaneous squamous cell carcinomas arise directly from pre-existing actinic keratoses.

---

Treatment Strategies for Actinic Keratosis: Cryotherapy vs. Field Therapy

Therapeutic management is stratified into lesion-directed destruction (for isolated, discrete lesions) and field-directed therapy (for multiple lesions or extensive field cancerization).

                  ACTINIC KERATOSIS TREATMENT SELECTION

                       Assess Number of Lesions & Field
                                      │
            ┌─────────────────────────┴─────────────────────────┐
            ▼                                                   ▼
   ISOLATED LESIONS (<5 Discrete)             EXTENSIVE FIELD CANCERIZATION
   • Cryotherapy (Liquid Nitrogen)            (Multiple AKs, diffuse sun damage)
     - Open spray technique                                     │
     - Freeze-thaw cycle 5-10 sec                               ▼
     - Excellent cure (>95%)                  FIELD-DIRECTED PHARMACOTHERAPY
                                              1. Topical 5-Fluorouracil (5-FU 5%)
                                                 BID for 2 to 4 weeks (Gold Standard!)
                                              2. Topical Imiquimod 3.75% or 5%
                                              3. Photodynamic Therapy (ALA + Light)

1. Lesion-Directed Therapy: Liquid Nitrogen Cryotherapy

• Technique: Liquid nitrogen (-196°C) applied via an open spray canister, holding the nozzle 1 cm from the lesion and freezing until a 1- to 2-mm ice halo forms around the margin, maintaining the freeze for 5 to 10 seconds, followed by complete thawing.
• Indications: The first-line, gold-standard therapy for isolated, individual, discrete actinic keratoses (<5 lesions).
• Mechanism & Sequelae: Intracellular ice crystal formation shears cell membranes, inducing vascular stasis and keratinocyte necrosis. Patients should be warned of blistering, crusting, and potential permanent localized hypopigmentation.

2. Field-Directed Therapy: Topical 5-Fluorouracil (5-FU)

• The Concept of Field Cancerization: Chronic UV exposure induces genetic mutations throughout an entire anatomical zone (e.g., the entire bald scalp or forehead), resulting in widespread subclinical atypia surrounding visible AKs. Treating only individual visible spots leaves subclinical dysplastic cells untouched.
• Topical 5-Fluorouracil (5-FU 5% Cream - Efudex):
  • Mechanism: A fluorinated pyrimidine antimetabolite that irreversibly inhibits thymidylate synthase, halting thymidine nucleotide synthesis, DNA replication, and RNA processing in rapidly dividing atypical keratinocytes.
  • Application: Applied thinly to the entire affected anatomical field twice daily for 2 to 4 weeks.
  • Patient Counseling on the Expected Inflammatory Response (Crucial Board Clue!): Clinicians must rigorously educate patients that 5-FU induces an intense, sequential four-stage inflammatory reaction:
    1. Erythema (days 3-7);
    2. Vesiculation & Blistering (days 7-14);
    3. Erosion, Ulceration & Necrosis (days 14-21; the skin appears severely burned and raw);
    4. Re-epithelialization & Healing (weeks 3-6 post-treatment).
    • Patients must understand that this dramatic, unsightly, and uncomfortable inflammatory response is expected and directly correlates with successful eradication of premalignant cells.

3. Alternative Field Therapies

• Topical Imiquimod (3.75% or 5% Cream): An immune-response modifier that acts as an agonist at Toll-like receptor 7 (TLR-7), stimulating local plasmacytoid dendritic cells to secrete interferon-alpha, IL-12, and TNF-alpha, triggering a T-cell-mediated antitumor immune response. Applied 2 to 3 times weekly for 4 to 16 weeks.
• Photodynamic Therapy (PDT): Topical application of a photosensitizing prodrug (5-aminolevulinic acid [ALA]), which is preferentially metabolized by dysplastic keratinocytes into protoporphyrin IX. Subsequent illumination with a blue or red light source generates cytotoxic singlet oxygen free radicals, destroying atypical cells with minimal scarring.

---

Basal Cell Carcinoma: Subtypes, Presentation & Biopsy

Basal cell carcinoma (BCC) is the most common cancer in humans, accounting for approximately 75% to 80% of all non-melanoma skin malignancies. It arises from pluripotent stem cells in the basal layer of the interfollicular epidermis and hair follicle outer root sheath.

Molecular Drivers & Pathophysiology

• The hallmark molecular driver of BCC is aberrant, constitutive hyperactivation of the Sonic Hedgehog (SHH) signaling pathway.
• More than 90% of sporadic BCCs harbor loss-of-function mutations in the patched-1 (PTCH1) tumor suppressor gene on chromosome 9q22, or activating mutations in the smoothened (SMO) proto-oncogene.
• Biologic Behavior: BCC is characteristically slow-growing and locally invasive, with deep tissue destruction if neglected. However, BCC has an extremely low metastatic potential (<0.01% to 0.1%), spreading to regional lymph nodes or lungs only in extreme, long-neglected tumors.

                     BASAL CELL CARCINOMA SUBTYPES

    NODULAR BCC (~60%)        SUPERFICIAL BCC (~20%)      MORPHEAFORM BCC (~10%)
   ┌────────────────────┐    ┌────────────────────┐    ┌────────────────────┐
   │ • Pearly / Shiny   │    │ • Erythematous     │    │ • Scar-like / Flat │
   │ • Rolled Borders   │    │ • Thin scaly patch │    │ • Indurated plaque │
   │ • Telangiectasias  │    │ • Thread-like rim  │    │ • Aggressive depth │
   │ • Central Ulcer    │    │ • Mimics Eczema    │    │ • Mohs Mandatory!  │
   └────────────────────┘    └────────────────────┘    └────────────────────┘

Clinical Subtypes

1. Nodular BCC (Most Common, ~60%):
   • Classic morphology: A firm, pearly or translucent, pink-to-flesh-colored dome-shaped papule or nodule with raised, rolled ("donut-like") borders;
   • Prominent arborizing telangiectatic vessels coursing across the surface;
   • As the tumor enlarges, the center frequently undergoes ischemic necrosis, developing central depression, ulceration, and crusting (the historical "rodent ulcer").
2. Superficial BCC (~15-30%):
   • Presents as a well-circumscribed, slowly enlarging, erythematous, dry, scaly patch or thin plaque, often with a fine, delicate, thread-like pearly border on close inspection;
   • Most common on the trunk and shoulders of younger adults;
   • Board Diagnostic Pitfall: Frequently misdiagnosed and mistreated as eczema, psoriasis, or tinea corporis. A scaly erythematous plaque that fails to respond to topical corticosteroids warrants a biopsy.
3. Morpheaform (Infiltrative / Sclerotic) BCC (~5-10%):
   • Presents as an indurated, firm, flat or slightly depressed, scar-like (sclerotic), ivory-white or yellowish plaque with ill-defined clinical borders;
   • Histologically characterized by narrow strands of basaloid cells deeply infiltrating a dense fibrous stroma;
   • Highly aggressive subtype with extensive subclinical microscopic extension far beyond visible clinical margins, carrying high recurrence rates.
4. Pigmented BCC:
   • Contains brown, blue, or black melanin pigment; easily confused with cutaneous melanoma.

Diagnostic Biopsy Technique for BCC

• Shave Biopsy: An elevated shave biopsy or saucerization shave is the preferred initial diagnostic technique for raised, exophytic, nodular or superficial lesions. It provides adequate architectural depth while leaving a clean cosmetic base.
• Punch Biopsy: Preferred for flat, indurated, morpheaform, or recurrent lesions where full-thickness dermal and subcutaneous architecture is needed to assess depth of invasion.

---

Management of BCC: Standard Excision, ED&C & Mohs Surgery

Selection of definitive treatment depends on tumor risk stratification based on anatomic location, tumor size, histologic subtype, and primary versus recurrent status.

Anatomic Risk Stratification: The Facial "H-Zone"

• High-Risk Locations ("H-Zone" / Mask Area of Face): Central face (eyelids, periorbital skin, nose, lips, chin, nasolabial folds), ears (auricle, retroauricular, canal), temples, preauricular cheek, hands, feet, and genitalia. High risk of subclinical invasion, recurrence, and cosmetic deformity.
• Moderate-Risk Locations ("M-Zone"): Cheeks, forehead, scalp, neck, and pretibial lower extremities.
• Low-Risk Locations ("L-Zone"): Trunk and extremities (excluding hands, feet, pretibial, and nails).

Therapeutic Modalities

---

Cutaneous Squamous Cell Carcinoma: Variants & Metastatic Risk

Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer, accounting for approximately 20% of non-melanoma skin malignancies. It represents an invasive malignant proliferation of epidermal keratinocytes capable of local tissue destruction and lymphatic metastasis.

Etiology & High-Risk Patient Populations

• Cumulative UV Radiation: Lifetime cumulative sun exposure is the primary driver, directly correlating with occupational outdoor work.
• Solid Organ Transplant Recipients (Crucial Board Pearl!): Immunosuppressed transplant patients have a 65- to 250-fold increased incidence of cutaneous SCC compared to the general population! In transplant recipients, SCC outnumbers BCC by 3:1 to 4:1, and tumors exhibit an exceptionally aggressive course with higher rates of recurrence and nodal metastasis.
• Marjolin Ulcer: Aggressive SCC arising within chronic, non-healing wounds, burn scars, venous stasis ulcers, or osteomyelitis sinus tracts. Characterized by latency of decades and a high metastatic rate (up to 30%).

Clinical Presentation & Variants

• Invasive SCC: A firm, indurated, flesh-colored to bright erythematous papule, nodule, or plaque with rough, adherent, thick hyperkeratotic scale or central ulceration with a firm, elevated, rolled margin. Frequently tender to palpation.
• Bowen Disease (Squamous Cell Carcinoma in Situ): A slowly enlarging, well-demarcated, erythematous, thin scaly plaque with irregular borders. Histology shows full-thickness epidermal dysplasia without invasion through the basement membrane.
• Keratoacanthoma (KA): Characterized by explosively rapid growth over 4 to 8 weeks, presenting as a symmetrical, dome-shaped, volcano-like nodule with a central crater filled with a prominent keratin plug. While KAs can regress spontaneously, they are biologically considered well-differentiated SCC variants and are treated with definitive surgical excision.

                 HIGH-RISK FEATURES FOR SCC METASTASIS

    ANATOMIC LOCATION        TUMOR PARAMETERS            HOST & HISTOLOGY
   ┌────────────────────┐   ┌────────────────────┐      ┌────────────────────┐
   │ • Vermilion Lip    │   │ • Diameter >2 cm   │      │ • Organ Transplant │
   │ • Ear (Helix)      │   │ • Breslow >2-4 mm  │      │ • Immunosuppressed │
   │ • Perineum/Genitals│   │ • Subcutaneous fat │      │ • Perineural Inv.  │
   │ • Marjolin Ulcer   │   │ • Recurrent tumor  │      │ • Poorly Differentiated
   └────────────────────┘   └────────────────────┘      └────────────────────┘

Management of Cutaneous SCC

• Standard Surgical Excision: For low-risk, small primary SCC on trunk/extremities: 4 to 6 mm margins of normal skin down into subcutaneous fat.
• Mohs Micrographic Surgery: First-line standard of care for all high-risk SCCs (H-zone of face, diameter >2 cm, ear or lip involvement, poorly differentiated histology, perineural invasion, recurrent tumors, or organ transplant recipients).
• Advanced/Metastatic SCC: Immune checkpoint inhibition with Cemiplimab or Pembrolizumab (monoclonal antibodies targeting programmed cell death-1 [PD-1]).

---

Melanoma Clinical Recognition: The ABCDE Criteria & Ugly Duckling Sign

Cutaneous melanoma is a malignant neoplasm arising from melanin-producing melanocytes. While accounting for only 1% to 2% of all skin malignancies, it is responsible for over 75% of skin cancer-related deaths.

Risk Factors

• Intermittent, intense UV radiation exposure and history of severe, blistering sunburns in childhood/adolescence;
• Fair skin phototypes (Fitzpatrick I-II: blue/green eyes, red/blond hair, freckling propensity);
• High melanocytic nevus count (>50 common nevi or >5 atypical/dysplastic nevi);
• Personal or family history of melanoma (first-degree relative confers a 2- to 3-fold increased risk);
• Genetic mutations: Germline mutations in CDKN2A (cyclin-dependent kinase inhibitor 2A, p16) or somatic mutations in BRAF (specifically the BRAF V600E mutation, found in ~50% of melanomas).

The ABCDE Diagnostic Framework

                      MELANOMA ABCDE CRITERIA

    [A] ASYMMETRY ──────────────> One half does not match the other half
    [B] BORDER IRREGULARITY ────> Edges are notched, scalloped, ragged, or blurred
    [C] COLOR VARIEGATION ──────> Multiple shades: brown, black, tan, blue, red, white
    [D] DIAMETER >=6 MM ────────> Larger than a pencil eraser (early may be smaller)
    [E] EVOLVING ───────────────> Documented change in size, shape, color, or symptoms
                                  (THE SINGLE MOST SENSITIVE CLINICAL INDICATOR!)

The "Ugly Duckling" Sign

• Most individuals have a dominant, uniform morphologic pattern for their melanocytic nevi. The "Ugly Duckling" sign posits that a pigmented lesion that looks visibly different from all the patient's other moles (an outlier in size, shade, or architecture) has an exceptionally high likelihood of representing melanoma and warrants immediate biopsy.

Clinical Subtypes

1. Superficial Spreading Melanoma (Most Common, ~70%): Characterized by a prolonged initial radial (horizontal) growth phase within the epidermis before vertical invasion occurs. Classically found on the backs of men and the lower extremities of women.
2. Nodular Melanoma (~15-20%): Characterized by an immediate vertical growth phase from inception without a preceding radial phase. Presents as a rapidly enlarging, darkly pigmented or amelanotic (pink/flesh-colored) dome-shaped nodule that frequently ulcerates and bleeds; carries a poor prognosis due to rapid deep invasion.
3. Lentigo Maligna / Lentigo Maligna Melanoma (~5-15%): Arises on chronically sun-damaged skin of elderly individuals (face, neck, forearms) as a slow-growing, large, flat, asymmetric mottled brown patch (Lentigo Maligna = melanoma in situ).
4. Acral Lentiginous Melanoma (~2-5%):
   • Located on palmar, plantar, or subungual nail bed skin;
   • The most common subtype of melanoma in individuals with darker skin phototypes (African, Asian, and Hispanic populations), accounting for up to 50% to 70% of melanomas in these groups;
   • Not associated with UV radiation;
   • Hutchinson Sign: Longitudinal melanonychia (pigmented longitudinal nail band) with extension of black or brown pigment onto the adjacent proximal or lateral periungual nail fold, highly suspicious for subungual melanoma.

---

Diagnostic Biopsy Principles: The Excisional Gold Standard

[!IMPORTANT] THE GOLD-STANDARD BIOPSY TECHNIQUE FOR SUSPECTED MELANOMA When a pigmented lesion exhibits ABCDE criteria or an "Ugly Duckling" appearance, the preferred initial diagnostic procedure is a COMPLETE NARROW EXCISIONAL BIOPSY with a 1 to 3 mm margin of normal skin, extending into the subcutaneous fat.

• If the lesion is too large for primary complete excision, or is situated in a cosmetically sensitive site (face, digit), a full-thickness punch biopsy or deep incisional punch biopsy of the thickest, darkest, most clinically raised portion is acceptable.
• NEVER PERFORM A SUPERFICIAL SHAVE BIOPSY ON A SUSPECTED MELANOMA!
  • Performing a superficial horizontal shave biopsy transects the deep margin of the tumor, destroying the basement architecture and preventing the pathologist from accurately measuring the full Breslow depth.
  • Transection leads to inaccurate microstaging, false understaging, and inappropriate definitive treatment planning.
• Cryotherapy is strictly contraindicated for any undiagnosed suspicious pigmented lesion.

---

Breslow Thickness, Surgical Margins & Sentinel Node Biopsy

Breslow Depth: The Master Prognostic Indicator

• Measurement: Histologic vertical depth measured in millimeters from the top of the epidermal granular cell layer (or base of ulceration) down to the deepest invasive malignant melanocyte in the dermis or subcutaneous fat.
• Significance: Breslow depth is the single most powerful prognostic factor for primary localized cutaneous melanoma.

Definitive Surgical Wide Local Excision Margins

Once the primary biopsy confirms melanoma and provides the Breslow depth, definitive wide local excision must be performed with specific, evidence-based surgical margins measured radially from the lesion's edge:

Sentinel Lymph Node Biopsy (SLNB) Indications

• Sentinel lymph node biopsy is a specialized staging procedure utilizing radioactive radiotracer (Technetium-99m) and isosulfan/methylene blue dye to identify and biopsy the first draining lymph node(s) receiving lymphatic flow from the primary tumor site.
• Indications for SLNB:
  1. Breslow Depth >= 1.0 mm: Routine recommendation for all clinically node-negative patients (Stage IB and Stage II);
  2. Breslow Depth 0.8 to 1.0 mm WITH High-Risk Features: Recommended if tumor ulceration is present or if mitotic rate is elevated (>=1/mm²);
  3. Breslow Depth < 0.8 mm: SLNB is NOT routinely recommended because the probability of nodal micrometastasis is <5%, and SLNB does not confer survival benefit.

Adjuvant & Advanced Systemic Therapies

• Targeted Therapy: For patients with Stage III/IV melanoma harboring a BRAF V600E or V600K mutation, combined oral therapy with a BRAF inhibitor (Dabrafenib) and a MEK inhibitor (Trametinib) blocks downstream MAPK signaling, producing high initial response rates.
• Immune Checkpoint Inhibitors: Monoclonal antibodies targeting PD-1 (Pembrolizumab, Nivolumab) or CTLA-4 (Ipilimumab) unleash cytotoxic T-cell antitumor immunity, dramatically extending long-term overall survival in advanced melanoma.